Posted by Michael Wonder on 22 Nov 2021
FDA grants breakthrough designation for early stage breast cancer detection blood test developed by Datar Cancer Genetics
19 November 2021 - TriNetra is a circulating tumour cell detection blood test which is able to identify early stage breast cancer with high accuracy in women above the age of 40 years.
Datar Cancer Genetics today announced that the US FDA has granted 'breakthrough device designation' for its 'TriNetra blood test to detect early stage breast cancer.
